Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an update.
Hemogenyx Pharmaceuticals has announced a change in its company secretary and registered office as of January 2025. Ben Harber has resigned as Company Secretary, with Westend Corporate LLP taking over the role. Additionally, the company has relocated its registered office to 6 Heddon Street, London. These changes reflect the company’s ongoing efforts to streamline operations and enhance its corporate structure.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded biopharmaceutical company based in London, with subsidiaries in New York City. The company is focused on developing innovative therapies for blood and autoimmune diseases, aiming to expand the reach of bone marrow transplantation for patients with currently incurable life-threatening conditions.
Average Trading Volume: 33,049
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £14.19M
See more insights into HEMO stock on TipRanks’ Stock Analysis page.